VM
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Microcavity-assisted cloning (MAC) of hard-to-clone HepG2 cell lines : cloning made easy | BMC biotechnology | 2024 | 16 | 15 | |||
| 17q Gain in Neuroblastoma : A Review of Clinical and Biological Implications | Cancers | 2024 | 15 | 14 | |||
| Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11 | Frontiers in oncology | 2024 | 9 | 9 | |||
| GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation | Journal of cancer research and clinical oncology | 2022 | 382 | 173 | |||
| The Catalytic Activity of GSTM1 In vitro is Independent of MAPK8 | Drug metabolism letters | 2021 | 98 | 66 | |||
| A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma | Journal of experimental & clinical cancer research | 2021 | 244 | 198 | |||
| The analysis of GSTA1 promoter genetic and functional diversity of human populations | Scientific reports | 2021 | 277 | 216 | |||
| 4th ESPT Conference: pharmacogenomics and personalized medicine - research progress and clinical implementation | Pharmacogenomics | 2019 | 311 | 498 | |||
| The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review | International Journal of Molecular Sciences | 2019 | 332 | 266 | |||
| PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level | Journal of Experimental & Clinical Cancer Research | 2019 | 316 | 416 | |||
| 4th ESPT summer school: precision medicine and personalised health | Pharmacogenomics | 2019 | 270 | 124 | |||
| 11q deletion in neuroblastoma: a review of biological and clinical implications | Molecular Cancer | 2017 | 489 | 271 | |||
| Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT) | Drug Metabolism and Personalized Therapy | 2017 | 530 | 1 | |||
| GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study | Oncotarget | 2017 | 551 | 243 | |||
| The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation | Frontiers in Pharmacology | 2017 | 617 | 244 | |||
| 8th Santorini Conference: Systems medicine and personalized health and therapy, Santorini, Greece, 3-5 October 2016 | Drug Metabolism and Personalized Therapy | 2017 | 574 | 3 | |||
| Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use | International Journal of Molecular Sciences | 2016 | 581 | 434 | |||
| Creation of the Swiss group of pharmacogenomics and personalized therapy (SPT) | Paediatrica | 2016 | 375 | 82 |
